Atila BRCA1&2 Mutation Screening Kit

Hereditary breast and ovarian cancer (HBOC) syndrome is one of the most common inherited  cancer predisposition disorders worldwide and is primarily caused by pathogenic mutations in the BRCA1 and BRCA2 genes, which encode key proteins involved in DNA damage repair through homologous recombination. According to the World Health Organization (WHO), breast cancer is the most frequently diagnosed cancer globally, and inherited BRCA1/2 mutations substantially increase an individual’s lifetime risk of developing breast, ovarian, and other associated cancers. The prevalence of BRCA mutations varies among populations and ethnic groups, with certain recurrent mutations occurring at higher frequencies in specific regions or ancestries. Individuals carrying BRCA1 or BRCA2 mutations are at increased risk of early-onset disease, multiple primary cancers, and aggressive tumor phenotypes, contributing to significant morbidity and mortality. Early and accurate detection of clinically relevant BRCA1/2 mutations is therefore essential for hereditary cancer risk assessment, genetic counseling, personalized surveillance, and informed clinical management strategies.

The Atila BRCA1&2 Mutation Screening Kit is a multiplex real-time polymerase chain reaction (PCR) assay based on proprietary technology designed to improve the accuracy and efficiency of detecting selected pathogenic variants associated with hereditary breast and ovarian cancer syndrome. Multiple sets of oligonucleotides are specifically designed to detect and individually distinguish 38 predefined BRCA1 and BRCA2 variants, which are organized into several primer mixes (BRCAPMs). The assay enables the identification of individual variants within the coverage of each BRCAPM. The covered variants include clinically significant single nucleotide substitutions, small insertions and deletions, and splice-site variants, as listed in Table 1. This test is intended for screening for selected BRCA1/2 variants and may aid in the identification of individuals at increased genetic risk when used in conjunction with appropriate clinical evaluation and confirmatory testing.